drugset / Trial / NCT03762564
Study With Paclitaxel +/- Ramucirumab in Patients With Squamous-cell Carcinoma of the Esophagus After Prior Therapy
Phase 2
Completed
21 enrolled
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Eli Lilly and Company · collabTrium Analysis Online GmbH · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a multicenter, randomized, controlled, open-label phase II study including patients with squamous-cell carcinoma of the esophagus, refractory or intolerant to combination therapy with Fluoropyrimidine and Platinum-based drugs.
Timeline
- Start
- 2019-03-08
- Primary completion
- 2022-07-04
- Completion
- 2022-11-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Paclitaxel | Small molecule | 80 mg/m2 | Intravenous |
| Subject | Ramucirumab | Monoclonal antibody | 8 mg/kg | Intravenous |